Evidence map›Paper›PMID 21552485›Full record

ArticlePloS one2011

Living bacterial sacrificial porogens to engineer decellularized porous scaffolds.

Feng Xu, BanuPriya Sridharan, Naside Gozde Durmus, ShuQi Wang, Ahmet Sinan Yavuz, Umut Atakan Gurkan, Utkan Demirci

Abstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Bioinks for 3D bioprinting: an overview.Biomaterials science · 2018
    Review
  5. Article
  6. Review
  7. Article
  8. Bioprinting for stem cell research.Trends in biotechnology · 2013
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Feng XuDemirci Bio-Acoustic-MEMS in Medicine Laboratory, Department of Medicine, Center for Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
BanuPriya Sridharan
Naside Gozde Durmus
ShuQi Wang
Ahmet Sinan Yavuz
Umut Atakan Gurkan
Utkan Demirci

Funding

Antibody-based cell purification at resource limited setting for HIVR21AI087107 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DEMIRCI, UTKAN · 2010 to 2011
$488k
NIAID NIH HHS R21 AI087107
6 · The paper itself

Abstract

Decellularization and cellularization of organs have emerged as disruptive methods in tissue engineering and regenerative medicine. Porous hydrogel scaffolds have widespread applications in tissue engineering, regenerative medicine and drug discovery as viable tissue mimics. However, the existing hydrogel fabrication techniques suffer from limited control over pore interconnectivity, density and size, which leads to inefficient nutrient and oxygen transport to cells embedded in the scaffolds. Here, we demonstrated an innovative approach to develop a new platform for tissue engineered constructs using live bacteria as sacrificial porogens. E.coli were patterned and cultured in an interconnected three-dimensional (3D) hydrogel network. The growing bacteria created interconnected micropores and microchannels. Then, the scafold was decellularized, and bacteria were eliminated from the scaffold through lysing and washing steps. This 3D porous network method combined with bioprinting has the potential to be broadly applicable and compatible with tissue specific applications allowing seeding of stem cells and other cell types.

Indexed as

Microbial ViabilityAnimalsCell ProliferationEscherichia coliHydrogelsMiceNIH 3T3 CellsPorosityTissue EngineeringTissue ScaffoldsHydrogels

Identifiers

PMID21552485
PMCPMC3084297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.